Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX · Real-Time Price · USD
5.28
-0.47 (-8.17%)
At close: Jun 5, 2026, 4:00 PM EDT
5.38
+0.10 (1.89%)
After-hours: Jun 5, 2026, 7:54 PM EDT
Turn Therapeutics Employees
Turn Therapeutics had 2 employees as of December 31, 2025. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change
-2
Growth
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,918,253
Market Cap
157.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2 | - | - | 2 | 0 |
| Jun 30, 2025 | 2 | -2 | -50.00% | 2 | 0 |
| Jun 30, 2024 | 4 | - | - | 1 | 3 |
| Dec 31, 2023 | 4 | - | - | 1 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| ADC Therapeutics | 193 |
| ProQR Therapeutics | 187 |
| Innate Pharma | 164 |
| Tenaya Therapeutics | 70 |
| Precision BioSciences | 66 |
| Acumen Pharmaceuticals | 61 |
| OnKure Therapeutics | 45 |
TTRX News
- 3 days ago - Turn Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Turn announces interim analysis findings from Phase 2 trial of GX-03 - TheFly
- 6 days ago - Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Business Wire
- 11 days ago - Turn Therapeutics announces peer-reviewed article on GX-03 - TheFly
- 11 days ago - Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model - Business Wire
- 19 days ago - Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - Business Wire
- 20 days ago - Turn appoints Hahn as Executive Clinical, Regulatory Lead for GX-03 - TheFly
- 20 days ago - Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead - Business Wire